EM1031 / EpimAb Biotherap, Juri Biosciences - LARVOL DELTA

EM1031, a novel KLK2 x CD3 bispecific T-cell engager with highly effective efficacy in preclinical models (AACR 2025) - "In xenograft models derived from KLK2 positive prostate cancer cell lines, EM1031 completely eradicated tumors with lower cytokine release compared to the reference TCE. Taken together, these data suggest that EM1031 has the potential in the treatment of prostate cancer."

Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • KLK2

EpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual Meeting (GlobeNewswire) - "The posters will feature: 1) Clinical results for EMB-01, an EGFR x cMet bispecific antibody, in colorectal cancer; 2) Preclinical data for EM1031, a novel KLK2 x CD3 bispecific T-cell engager; 3) Preclinical data for a novel LY6G6D x CD3 bispecific T-cell engager and 4) Preclinical data for a novel TCR based bispecific platform."

P1/2 data • Preclinical • Colorectal Cancer